Dr. Holger N. Reithinger

FORBION Capital Partners / benannt als Vertretung für das BMWi

Holger is a partner in Forbion, a leading venture capital firm. Forbion invests in young, innovative life science start-ups that develop new drugs. Holger has more than 20 years of experience as an investor in life science companies and currently serves on the supervisory, advisory and member of the boards of Allecra GmbH, catalYm GmbH, OMEICOS GmbH, OMEICOS Ophthalmic Inc. and Gotham Therapeutics Inc. Previously, Holger served on the boards of numerous life science companies, including Curetis N.V. (IPO 2015), Cellnovo S.A., Cellnovo S.A. and Curetis N.V. (IPO 2015). (IPO 2015), Epigenomics (IPO 2004), MBT (assets sold to Medigene), 4SC (IPO 2005), NeurogesX (IPO 2007), Fibrex Medical (assets licensed to Ikaria), Agendia, Santaris (sold to Roche 2014) and Rigontec (sold to MSD 2017). Prior to his VC activities, Holger gained operational experience as a product development manager at Biometra/Whatman Plc, now part of GE Healthcare.


+49 (0)894 161 619 50